CN106361699A - Nasal spray product for treating or preventing cold and application thereof - Google Patents
Nasal spray product for treating or preventing cold and application thereof Download PDFInfo
- Publication number
- CN106361699A CN106361699A CN201610725847.5A CN201610725847A CN106361699A CN 106361699 A CN106361699 A CN 106361699A CN 201610725847 A CN201610725847 A CN 201610725847A CN 106361699 A CN106361699 A CN 106361699A
- Authority
- CN
- China
- Prior art keywords
- nasal spray
- weight portion
- compositionss
- agent
- spray product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a nasal spray product for treating or preventing cold, which includes a composition for treating or preventing cold and a nasal spray container for accommodating the composition. Spray angle, which is formed through the container, of the composition is less than 30 degrees. The composition includes a gel substrate and a pH buffer agent. The pH of the composition is higher than 2.5 and lower than 4.0. The invention also provides an application of the composition in preparation of a medicine for treating or preventing cold, wherein the composition can prevent cold and alleviate early-stage symptoms of the cold through physical effects.
Description
Technical field
The present invention relates to a kind of nasal spray product, described nasal spray product includes the group for treatment or preventing cold
Compound and the nasal spray container accommodating described compositionss.The compositionss of the present invention do not conform to any active pharmaceutical ingredients, by thing
Reason model of action prevention and alleviation cold symptoms.The invention still further relates to the purposes of described compositionss.
Background technology
Flu is the common respiratory tract disease being caused by cold virus, starts from viruses contact nose or larynx mucosa, and body is exempted from
Epidemic disease system discharges a large amount of leukocyte to anti-inflammatory, and cardinal symptom is sneeze, rhinorrhea, nasal obstruction, throat pain, cough, headache, fear
Tremble with fear and myalgia.Flu has very strong infectiousness, mainly passes through air droplet transmission virus.
The medicine for the treatment of flu includes antiviral agents, such as difficult to understand and Si Tawei, acyclovir and amantadine；Treatment fever
The medicine of nasal obstruction, such as acetaminophen, chlorphenamine and diphenhydramine；And the Chinese medicine of heat-clearing and toxic substances removing, such as Yinqiao detoxification, Baphicacanthus cusia
Root and the clear pestilence of Flos Nelumbinis.
Below it is all that the curative effect controlling flu is reached by Drug therapy.However, being caught a cold generally to people by Drug therapy
Body has certain injury, and for example, medicine can cause necessarily to injure to the liver of human body, kidney and other organs.In order to overcome prior art
The shortcoming of middle utilization Drug therapy flu, medical market is deposited to preventing and treating flu by simply and easily physical method
In demand.
Content of the invention
It is an object of the invention to provide a kind of nasal spray product for treatment or preventing cold, described nasal spray product
Product include the compositionss and the nasal spray container accommodating described compositionss for treatment or preventing cold, and described compositionss are passed through
30 ° of the jet angle ＜ that nasal spray container is formed, wherein said compositionss include gel-type vehicle and ph buffer agent, described compositionss
Ph more than 2.5 and be less than 4.0.
Described nasal spray container can be, for example, spray bottle well known in the prior art.
In embodiments of the invention, the compositionss of the present invention can include following composition in parts by weight: solidifying
Gel matrix 0.01-20 weight portion, ph buffer agent 0.01-5 weight portion.
In a preferred embodiment of the invention, the compositionss of the present invention can include becoming as follows in parts by weight
Point: gel-type vehicle 0.05-5 weight portion, ph buffer agent 0.01-3 weight portion.
Gel-type vehicle in the compositionss of the present invention is selected from methylcellulose, ethyl cellulose, Hydroxypropyl Cellulose, hydroxypropyl
Methylcellulose, Polyvinylpyrrolidone-vinyl acetate co-polymer, hyaluronic acid, poloxamer, carrageenan, arabic gum, card
One or more of ripple nurse, polyvinyl pyrrolidone and pectin.
Ph buffer agent in the compositionss of the present invention be selected from citric acid and sodium citrate, succinic acid and disodium succinate,
One or more pairs of in sodium dihydrogen phosphate and disodium hydrogen phosphate.
In a preferred embodiment of the present invention, the compositionss of the present invention can also include becoming as follows in parts by weight
Point: osmotic pressure regulator 0-10 weight portion, surfactant 0-10 weight portion, wetting agent 0-20 weight portion, antiseptic and inhibiting bacteria function agent 0-2
Weight portion.
In further preferred embodiment of the present invention, the compositionss of the present invention can also include in parts by weight
Following composition: osmotic pressure regulator 0-5 weight portion, surfactant 0.02-5 weight portion, wetting agent 0.1-10 weight portion, anti-corrosion
Antibacterial 0-1 weight portion.
Described osmotic pressure regulator is selected from one or more of sodium chloride, glucose and potassium chloride.
Described wetting agent is selected from glycine betaine, 2-pyrrolidone-5-carboxylic acid, glycerol, propylene glycol, carbamide and hyaluronic acid
One or more.
Described surfactant is selected from one or more of poloxamer, tween and span.
Described antiseptic and inhibiting bacteria function agent is selected from methyl hydroxybenzoate, propylparaben, benzoic acid, benzyl alcohol, polyhexamethylene
One or more of biguanide and benzalkonium chloride.
In a preferred embodiment of the invention, the compositionss of the present invention can also include assisting in parts by weight
Point 0.005-5 weight portion, wherein auxiliary element be selected from one of cytotrophy agent, freshener, correctivess, skin contraction agent or
Multiple.
Described cytotrophy agent includes acetone acid compounds, and wherein said acetone acid compounds are selected from acetone acid
One or more of potassium, Sodium Pyruvate and calcium pyruvate.
Described freshener is selected from Oleum menthae, menthol, eucalyptus oil, Camphora, one or more of ws-23, ws-3.
Described correctivess are selected from Herba Menthae, Fructus Citri Limoniae essence, fragrant citrus essence, sucralose, acesulfame potassium and aspartame
One or more.
Described skin contraction agent is selected from one or more of tannic acid, silver nitrate, edetic acid zinc and zinc sulfate.
It is yet another object of the invention to provide use in the medicine that preparation is used for treatment or preventing cold for the above-mentioned composition
On the way.
It is a further object of the present invention to provide a kind of method preparing compositionss of the present invention, comprise the following steps:
1. gel-type vehicle is added to fully dispersed in the purified water (70-95 DEG C) of heat, then adding purified water makes it fill
Divide swelling；
2. unclassified stores is added in purified water, standby after stirring and dissolving；
3. by step 1. with step 2. two parts mix homogeneously；
4. and then by solution load in nasal spray container.
The compositionss of the present invention pass through physical mode of action, strengthen the ability that human body intercepts and removes cause of disease, preventing cold
Generation, also can alleviate cold symptoms.Additionally, nasal spray product convenient drug administration, nonirritant and the sensitization of the present invention, peace
Entirely effective.
Brief description
Fig. 1 is the jeting effect figure of the not diluted sample of the embodiment of the present invention 8.
Fig. 2 is the jeting effect figure of the sample a after the dilution of the embodiment of the present invention 8.
Fig. 3 is the jeting effect figure of the sample f after the dilution of the embodiment of the present invention 8.
Fig. 4 is the jeting effect figure of the sample h after the dilution of the embodiment of the present invention 8.
Specific embodiment
The following example further explains the present invention, but, they and be not meant to limit the scope of the invention or
Limit.
Gel-type vehicle (Polyvinylpyrrolidone-vinyl acetate co-polymer, hypromellose used in following examples
Plain k100/k15m/k4m/e4m/e10m/e5, carrageenan) it is purchased from DOW Chemical (Chinese) Investment Co., Ltd；Ph buffer agent (amber
Amber acid and disodium succinate (analysis is pure), citric acid and sodium citrate (pharmaceutical grade), sodium dihydrogen phosphate and disodium hydrogen phosphate (analysis
Pure)) purchased from Rizhao Luxin RZBC Co., Ltd. and traditional Chinese medicinesization examination.
Used in following examples, " purified water of heat " refers to the purified water that temperature is 70-95 DEG C.Except non-invention
Particularly pointing out used purified water is " purified water of heat ", and otherwise the purified water described in other parts of the present invention refers both under room temperature
Purified water, wherein room temperature refers to 25 DEG C ± 3 DEG C.
Embodiment 1
In the present embodiment, the proportioning of the compositionss of the present invention is as shown in table 1 below:
Table 1
Preparation technology:
1. Polyvinylpyrrolidone-vinyl acetate co-polymer is dissolved in fully dispersed in the purified water of 30g heat, then
Adding 20g purified water makes it fully swelling；
2. glycerol, Oleum menthae, Tween 80, edetic acid zinc, sodium chloride, succinic acid and disodium succinate are dissolved in 30g pure
Change in water；
3. by step 1. with step 2. two parts mix homogeneously, plus purified water to total solution weight is 100g；
4. and then by solution load in spray bottle.
After testing, the ph value of prepared compositionss is 3.6.
Embodiment 2
In the present embodiment, the proportioning of the compositionss of the present invention is as shown in table 2 below:
Table 2
| Composition | Specific name | Weight |
| Gel-type vehicle | Hypromellose | 0.1g |
| Osmotic pressure regulator | Glucose | 2g |
| Wetting agent | 2-pyrrolidone-5-carboxylic acid | 1g |
| Surfactant | tween 80 | 0.5g |
| Auxiliary element-correctivess | Aspartame | 0.4g |
| Auxiliary element-correctivess | Acesulfame potassium | 0.4g |
| Ph buffer agent | Citric acid | 0.03g |
| Ph buffer agent | Sodium citrate | 0.01g |
| Auxiliary element-freshener | ws-23 | 0.02g |
| Auxiliary element-cytotrophy agent | Sodium Pyruvate | 1g |
| Solvent | Purified water | The ad pond om that adds water is 100g |
Preparation technology:
1. gel-type vehicle is added to fully dispersed in the purified water of 30g heat, then adding 20g purified water makes it fully molten
Swollen；
2. unclassified stores is added in 30g purified water, standby after stirring and dissolving；
3. by step 1. with step 2. two parts mix homogeneously, plus purified water to total solution weight is 100g；
4. and then by solution load in spray bottle.
After testing, the ph value of prepared compositionss is 3.5.
Embodiment 3
In the present embodiment, the proportioning of the compositionss of the present invention is as shown in table 3 below:
Table 3
Preparation technology is with embodiment 2.
After testing, the ph value of prepared compositionss is 3.0.
Embodiment 4
In the present embodiment, the proportioning of the compositionss of the present invention is as shown in table 4 below:
Table 4
Preparation technology is with embodiment 2.
After testing, the ph value of prepared compositionss is 2.8.
Embodiment 5
In the present embodiment, the proportioning of the compositionss of the present invention is as shown in table 5 below:
Table 5
Preparation technology is with embodiment 2.
After testing, the ph value of prepared compositionss is 3.4.
Embodiment 6
In the present embodiment, the proportioning of the compositionss of the present invention is as shown in table 6 below:
Table 6
| Composition | Specific name | Concrete weight |
| Gel-type vehicle | Carrageenan | 0.3g |
| Osmotic pressure regulator | Sodium chloride | 0.9g |
| Auxiliary element-cytotrophy agent | Sodium Pyruvate | 0.5g |
| Ph buffer agent | Sodium citrate | 0.01 |
| Ph buffer agent | Citric acid | 0.06 |
| Antiseptic and inhibiting bacteria function agent | Poly hexamethylene biguanide | 0.001g |
| Auxiliary element-freshener | ws-3 | 0.025g |
| Auxiliary element-skin contraction agent | Silver nitrate | 0.2g |
| Solvent | Pure water | The ad pond om that adds water is 100g |
Preparation technology is with embodiment 2.
After testing, the ph value of prepared compositionss is 3.5.
Embodiment 7
In the present embodiment, the proportioning of the compositionss of the present invention is as shown in table 7 below:
Table 7
Preparation technology is with embodiment 2.
After testing, the ph value of prepared compositionss is 2.5.
Embodiment 8
In order to study the jet angle of the buffer capacity, viscosity and its nasal spray product of the present composition, using enforcement
The sample of example 5, dilutes different multiples (1: 0.5,1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 10) respectively with purified water and obtains respectively
To sample a-h, wherein not diluted sample is referred to as former state.The viscosity of detection each sample, spray angle, ph and osmotic pressure, knot
Fruit is summarized as follows table 8:
Table 8
Result shows, the compositionss of the present invention, in the case of 10 times of dilute with water, remain to keep buffer capacity and ph
＜ 4.Knowable to viscosity, the testing result of spray angle, the viscosity of product is bigger, spray angle is less, 30 ° of spray angle ＜
When, hydrojet is linear, can reach nasal cavity root, alleviates nasal obstruction phenomenon, and can form layer of gel layer in nasal cavity
Thus preventing the invasion and attack further of cold virus.
Embodiment 9: efficiency evaluation
This research is that one random, double blinding, placebo, parallel check experiment, evaluate the effectiveness of the compositionss of the present invention
And safety.Determine clinical trial case load, the early stage cold patients of screening all ages and classes level according to statistics, be randomly divided into
Test group and matched group.Test group uses the compositionss of the present invention (embodiment 2, embodiment 3, embodiment 4 and embodiment 5), right
Use placebo (purified water) according to group.1-2 hour uses 1 time, and every side nostril 2-3 spray, daily at least using 6 times, continues every time
Using 3 days.During first use, access times can be increased as one sees fit.The symptom and sign of record experimenter and laboratory examination results,
Evaluate curative effect, record cold symptoms score and all of " adverse events ".
The Symptoms of flu are: throat pain, nasal obstruction, watery nasal discharge, cough, sneeze, headache, myalgia, fear of cold.According to
The standards of grading that jackson formulates score to these cold symptoms orders of severity:
(1) 0 point=no: 24 hours no any symptoms；
(2) 1 points=gentle: sensitive, but will not uneasy or stimulation；
(3) 2 points=moderate: sometimes have discomforting symptom or stimulation；
(4) 3 points=serious: there are discomforting symptom and stimulation the most of the time.
Test result is as shown in the following Table 9.
Table 9
Outcome measure index
Curative effect index: common cold symptoms indices disappearance rate and persistent period；
Secondary efficacy index: cold symptoms total mark Assessment of Changes.
Clinical efficacy presses clinic control, effective, progress, invalid 4 grades of evaluations.
Clinic control: clinical symptom disappearance integration improves > 75%；
Effective: clinical symptoms control substantially, integrate and be improved as 50%-75%；
Progressive: clinical symptoms make moderate progress, integrate and be improved as 25%-50%；
Invalid: integration improves ＜ 25%.
Improve result as shown in table 10 below.
Table 10
| 2 groups of embodiment | 3 groups of embodiment | 4 groups of embodiment | 5 groups of embodiment | Matched group | |
| Improvement rate | 72% | 78% | 74% | 82% | 25% |
Adverse events statistics is as shown in table 11 below.
Table 11
As can be seen from the above results, the compositionss of the present invention are high to mitigating common cold initial stage symptom effect is significant.
Embodiment 10: safety evaluatio
Vitro cytotoxicity: respectively the composition sample cell culture fluid of embodiment 1-5 is diluted to 1mg/ml, according to
" gb/t 16886.5-2003 BiologicalEvaluationofMedicalDevice the 5th part vitro cytotoxicity test " method is checked.Respectively by sample
Product test liquid 37 DEG C ± 2 DEG C of cultured cells of contact, 48h, evaluation criterion such as table 12 below:
Table 12
| Cytotoxicity is scored | Implication |
| 0 | No cytotoxicity |
| 1 | Slight cytotoxic |
| 2 | Moderate cytotoxicity |
| 3 | Severe cytotoxicity |
Zest: respectively by the composition sample of embodiment 1-5, with reference to " gb/t 16886.10-2005 medical apparatus and instruments are given birth to
Thing evaluate the 10th part: stimulate with delayed hypersensitivity test " specify method inspection.
Sensitization: respectively by the composition sample of embodiment 1-5, with reference to " gb/t 16886.10-2005 medical apparatus and instruments are given birth to
Thing evaluate the 10th part: stimulate with delayed hypersensitivity test " specify maximal dose sensitization test (STT) method inspection.
Safety examination result is as shown in table 13 below:
Table 13
| Sample number | Vitro cytotoxicity | Zest | Sensitization |
| Embodiment 1 | 2 | Nonirritant | No sensitization |
| Embodiment 2 | 2 | Nonirritant | No sensitization |
| Embodiment 3 | 1 | Nonirritant | No sensitization |
| Embodiment 4 | 1 | Nonirritant | No sensitization |
| Embodiment 5 | 1 | Nonirritant | No sensitization |
By above assay, the compositionss of the present invention are safer, nonirritant and sensitization.
Claims (15)
1. a kind of for treatment or preventing cold nasal spray product it is characterised in that: described nasal spray product include use
In compositionss and the nasal spray container accommodating described compositionss for the treatment of or preventing cold, described compositionss pass through nasal spray
30 ° of the jet angle ＜ that container is formed, wherein said compositionss include gel-type vehicle and ph buffer agent, and the ph of described compositionss exists
More than 2.5 and be less than 4.0.
2. nasal spray product according to claim 1 it is characterised in that: in described compositionss, in parts by weight,
Gel-type vehicle is 0.01-20 weight portion, and ph buffer agent is 0.01-5 weight portion, preferably gel-type vehicle 0.05-5 weight portion, and ph delays
Electuary 0.01-3 weight portion.
3. nasal spray product according to claim 1 and 2 it is characterised in that: described gel-type vehicle is macromolecular material,
Described macromolecular material is selected from: methylcellulose, ethyl cellulose, Hydroxypropyl Cellulose, Hypromellose, polyvinylpyrrolidine
Ketone-vinyl acetate co-polymer, hyaluronic acid, poloxamer, carrageenan, arabic gum, Carbomer, polyvinyl pyrrolidone and
One or more of pectin.
4. nasal spray product according to claim 1 and 2 it is characterised in that: described ph buffer agent be selected from citric acid and
One or more pairs of in sodium citrate, succinic acid and disodium succinate, sodium dihydrogen phosphate and disodium hydrogen phosphate.
5. nasal spray product according to claim 1 and 2 it is characterised in that: described compositionss are according further to parts by weight
Meter includes: osmotic pressure regulator 0-10 weight portion, surfactant 0-10 weight portion, wetting agent 0-20 weight portion, antiseptic and inhibiting bacteria function
Agent 0-2 weight portion, preferably osmotic pressure regulator 0-5 weight portion, surfactant 0.02-5 weight portion, wetting agent 0.1-10 weight
Part, antiseptic and inhibiting bacteria function agent 0-1 weight portion.
6. nasal spray product according to claim 5 it is characterised in that: described osmotic pressure regulator be selected from sodium chloride,
One or more of glucose and potassium chloride.
7. nasal spray product according to claim 5 it is characterised in that: described wetting agent be selected from glycine betaine, pyrrolidine
One or more of keto carboxylic acid, glycerol, propylene glycol, carbamide and hyaluronic acid.
8. nasal spray product according to claim 5 it is characterised in that: described surfactant be selected from poloxamer,
One or more of tween and span.
9. nasal spray product according to claim 5 it is characterised in that: described antiseptic and inhibiting bacteria function agent be selected from Metagin
One or more of ester, propylparaben, benzoic acid, benzyl alcohol, poly hexamethylene biguanide and benzalkonium chloride.
10. nasal spray product according to claim 5 it is characterised in that: described compositionss are according further to parts by weight meter
Including auxiliary element 0.005-5 weight portion, described auxiliary element is selected from cytotrophy agent, freshener, correctivess, skin contraction agent
One or more of.
11. nasal spray products according to claim 10 it is characterised in that: described cytotrophy agent includes acetone acids
Compound.
12. nasal spray products according to claim 11 it is characterised in that: described acetone acid compounds be selected from acetone
One or more of sour potassium, Sodium Pyruvate and calcium pyruvate.
13. compositionss preparation for treatment or preventing cold medicine in purposes it is characterised in that: described compositionss include
Gel-type vehicle and ph buffer agent, the ph of described compositionss and is less than 4.0 more than 2.5.
14. purposes according to claim 13 it is characterised in that: in described compositionss, in parts by weight, gel base
Matter is 0.01-20 weight portion, and ph buffer agent is 0.01-5 weight portion, preferably gel-type vehicle 0.05-5 weight portion, ph buffer agent
0.01-3 weight portion.
15. purposes according to claim 13 or 14 it is characterised in that: described gel-type vehicle is macromolecular material, described
Macromolecular material is selected from: methylcellulose, ethyl cellulose, Hydroxypropyl Cellulose, Hypromellose, Polyvinylpyrrolidone-
Vinyl acetate co-polymer, hyaluronic acid, poloxamer, carrageenan, arabic gum, Carbomer, polyvinyl pyrrolidone and fruit
One or more of glue；Described ph buffer agent is selected from citric acid and sodium citrate, succinic acid and disodium succinate, di(2-ethylhexyl)phosphate
One or more pairs of in hydrogen sodium and disodium hydrogen phosphate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610725847.5A CN106361699A (en) | 2016-08-25 | 2016-08-25 | Nasal spray product for treating or preventing cold and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610725847.5A CN106361699A (en) | 2016-08-25 | 2016-08-25 | Nasal spray product for treating or preventing cold and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106361699A true CN106361699A (en) | 2017-02-01 |
Family
ID=57879386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610725847.5A Pending CN106361699A (en) | 2016-08-25 | 2016-08-25 | Nasal spray product for treating or preventing cold and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106361699A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110507603A (en) * | 2019-09-12 | 2019-11-29 | 沈阳大得医疗器械产品有限公司 | A kind of solidification seawater gel and preparation method thereof |
| CN111603480A (en) * | 2020-07-02 | 2020-09-01 | 王浏胜 | Nasal wash |
| CN115721726A (en) * | 2022-07-27 | 2023-03-03 | 江苏长泰药业有限公司 | Nasal cavity product for preventing or relieving cold symptoms and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101426531A (en) * | 2006-04-21 | 2009-05-06 | 东兴药品工业株式会社 | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation |
| CN101933963A (en) * | 2010-09-03 | 2011-01-05 | 南方医科大学 | Nasal in-situ gel for treating headache |
| CN102657611A (en) * | 2012-03-02 | 2012-09-12 | 江苏长泰药业有限公司 | Sodium pyruvate nasal spray and preparation method thereof |
-
2016
- 2016-08-25 CN CN201610725847.5A patent/CN106361699A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101426531A (en) * | 2006-04-21 | 2009-05-06 | 东兴药品工业株式会社 | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation |
| CN101933963A (en) * | 2010-09-03 | 2011-01-05 | 南方医科大学 | Nasal in-situ gel for treating headache |
| CN102657611A (en) * | 2012-03-02 | 2012-09-12 | 江苏长泰药业有限公司 | Sodium pyruvate nasal spray and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110507603A (en) * | 2019-09-12 | 2019-11-29 | 沈阳大得医疗器械产品有限公司 | A kind of solidification seawater gel and preparation method thereof |
| CN111603480A (en) * | 2020-07-02 | 2020-09-01 | 王浏胜 | Nasal wash |
| CN115721726A (en) * | 2022-07-27 | 2023-03-03 | 江苏长泰药业有限公司 | Nasal cavity product for preventing or relieving cold symptoms and preparation method thereof |
| CN115721726B (en) * | 2022-07-27 | 2023-10-17 | 江苏长泰药业股份有限公司 | Nasal product for preventing or relieving cold symptoms and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090191288A1 (en) | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | |
| EP2214658B1 (en) | Osmolyte-containing preparation for use in case of dry mucous membranes | |
| EP3370692B1 (en) | Stuffy nose deblocking composition having antiviral activity | |
| US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
| EP2385835B1 (en) | Use of deuterium oxide for treating viral diseases of the eye | |
| CN107362141B (en) | A kind of Anefrin Nasal Spray and preparation method thereof | |
| CN106361699A (en) | Nasal spray product for treating or preventing cold and application thereof | |
| DE102007040615A1 (en) | Osmolyte for the treatment of allergic or viral respiratory diseases | |
| ES2272689T3 (en) | DIHYDRO-TRITERPENS IN THE TREATMENT OF VIRAL INFECTIONS, CARDIOVASCULAR DISEASE, INFLAMMATION, HYPERSENSITIVITY OR PAIN. | |
| CN105193837B (en) | A kind of creme and preparation method thereof of prevention and treatment joint disease | |
| CN110123989A (en) | A kind of application of curcuma zedoary essential oil | |
| CN104147603A (en) | Application of novel marine algae extractive composition in preventing virus flu | |
| KR20240016954A (en) | Composition and method for treating conditions using fractionated honey | |
| EP2985019B1 (en) | Nasal composition having anti-viral properties | |
| RU2479318C1 (en) | Method for preparing drug and biologically active preparations | |
| CN109381449A (en) | A kind of dermatitis antibacterial film forming spray and preparation method thereof | |
| DE602004004085T2 (en) | USE OF SODIUM-2-MERCAPOTETHANSULPHONATE AS ANTIVIRAL AGENT | |
| EP3129031B1 (en) | Composition for treating stomach pain | |
| EP2985027B1 (en) | Nasal composition comprising mixture of hyaluronic acids and saline solution | |
| EP2385834B1 (en) | Use of deuterium oxide for treating viral diseases of the respiratory tract | |
| CN107898809A (en) | A kind of Zinc calcium gluconate oral solution and preparation method thereof | |
| CN106924175A (en) | A kind of pharmaceutical composition for treating multiple sclerosis | |
| CN117797168A (en) | Allergen-isolated nasal composition | |
| CN108012530A (en) | For treating the preparation of mucosa injury | |
| Chakraborty et al. | In vivo Study of Insulin-loaded Microemulsion Topical gel with Aloe vera for the Treatment of Dermatologic Manifestation of Diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |